The Role of Pharmacists in Opioid Addiction Management

Pallav Dave

doi:10.22270/ajdhs.v4i1.71

Authors

Pallav Dave Regulatory Compliance Analyst, Louisville, KY, 40223, USA

DOI:

https://doi.org/10.22270/ajdhs.v4i1.71

Keywords:

opioids, opioid addiction management, pharmacists, opioid misuse, opioid use disorder

Abstract

Opioid addiction claims thousands of lives every year in the United States. The prevalence of misuse, abuse, and overdose continues to rise despite the measures and initiatives taken by the federal government and other government agencies to manage the problem. These efforts have led to a re-evaluation of the role different healthcare providers can play to ensure the problem is adequately addressed. Being one of the most accessible healthcare providers to patients under opioid therapy, pharmacists are better positioned to deal with opioid addiction. They dispense millions of opioids every year making them better positioned to screen for patients who are likely to develop an addiction problem and refer them to treatment resources before the abuse escalates to opioid use disorder (OUD). The aim of this review is to explore the role of pharmacists in opioid addiction management including prevention, screening, education, naloxone prescribing, counselling, and referral to treatment resources. The review also provides pertinent information regarding the current state of the opioid crisis in the US, including recent data on prevalence and opioid-related deaths. Exploring the role of pharmacists is instrumental in coming up with effective measures that can help in opioid addiction management.

Keywords: opioids, opioid addiction management, pharmacists, opioid misuse, opioid abuse, opioid use disorder

Author Biography

Pallav Dave, Regulatory Compliance Analyst, Louisville, KY, 40223, USA

Regulatory Compliance Analyst, Louisville, KY, 40223, USA

References

Busse JW, Wang L, Kamaleldin M, et al. Opioids for chronic noncancer pain: a systematic review and meta-analysis. JAMA. 2018; 320(23):2448-2460. https://doi.org/10.1001/jama.2018.18472 PMid:30561481 PMCid:PMC6583638

Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician. 2008;11(2S): S133. https://doi.org/10.36076/ppj.2008/11/S133

Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2022 National Survey on Drug Use and Health, NSDUH Series H-58, HHS Publication No. PEP23-07-01-006. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2023.

National Institute of Drug Abuse. Drug overdose death rates. 2022. Accessed February 28, 2024. https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates#:~:text=Opioid%2Dinvolved%20overdose%20deaths%20rose

Spencer MR, Miniño AM, Warner M. Drug overdose deaths in the United States, 2001-2021. NCHS Data Brief, no 457. Hyattsville, MD: National Center for Health Statistics. 2022. https://doi.org/10.15620/cdc:122556

Gomes T, Ledlie S, Tadrous M, Mamdani M, Paterson JM, Juurlink DN. Trends in opioid toxicity-related deaths in the US before and after the start of the COVID-19 pandemic, 2011-2021. JAMA Network Open. 2023;6(7): e2322303. https://doi.org/10.1001/jamanetworkopen.2023.22303 PMid:37418260 PMCid:PMC10329206

Gomes T, Tadrous M, Mamdani MM, Paterson JM, Juurlink DN. The burden of opioid-related mortality in the United States. JAMA Network Open. 2018; 1(2): e180217. https://doi.org/10.1001/jamanetworkopen.2018.0217 PMid:30646062 PMCid:PMC6324425

Centers for Disease Control and Prevention. The economics of injury and violence prevention; cost of opioid overdose and use disorder. 2023. Accessed February 28, 2024. https://www.cdc.gov/injury/features/health-econ-cost-of-injury/index.html#Cost-Opioid .

Gondora N, Versteeg SG, Carter C, et al. The role of pharmacists in opioid stewardship: A scoping review. Research in Social and Administrative Pharmacy. 2022; 18(5):2714-47. https://doi.org/10.1016/j.sapharm.2021.06.018 PMid:34261590

Chisholm-Burns MA, Spivey CA, Sherwin E, Wheeler J, Hohmeier K. The opioid crisis: origins, trends, policies, and the roles of pharmacists. American Journal of Health-System Pharmacy. 2019;76(7):424-35. https://doi.org/10.1093/ajhp/zxy089 PMid:31361827

Centers for Disease Control and Prevention.Opioid data analysis and resources. 2023. Accessed 28 February 2024. https://www.cdc.gov/opioids/data/analysis-resources.html

Centers for Disease Control and Prevention. Opioid overdose. 2023. Accessed 28 February 2024. https://www.cdc.gov/drugoverdose/deaths/opioid-overdose.html

Dart RC, Surratt HL, Cicero TJ, et al. Trends in opioid analgesic abuse and mortality in the United States. New England Journal of Medicine. 2015;372(3):241-8. https://doi.org/10.1056/NEJMsa1406143 PMid:25587948

International Narcotics Control Board. Narcotic drugs: estimated world requirements for 2017: statistics for 2015. Accessed February 28, 2024. https://www.incb.org/documents/Narcotic-Drugs/Technical-Publications/2016/Narcotic_Drugs_Publication_2016.pdf .

International Narcotics Control Board. Narcotic drugs: estimated world requirements for 2018: statistics for 2016. Accessed February 28, 2024. https://www.incb.org/documents/Narcotic-Drugs/Technical-Publications/2017/Narcotic_drugs_technical_publication_2017.pdf .

Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, Van Der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015; 156(4):569-76. https://doi.org/10.1097/01.j.pain.0000460357.01998.f1 PMid:25785523

Kaye AD, Jones MR, Kaye AM, et al. Prescription opioid abuse in chronic pain: an updated review of opioid abuse predictors and strategies to curb opioid abuse: part 1. Pain physician. 2017;20(2): S93. https://doi.org/10.36076/ppj.2017.s109

Unick GJ, Ciccarone D. US regional and demographic differences in prescription opioid and heroin-related overdose hospitalizations. International Journal of Drug Policy. 2017; 46:112-9. https://doi.org/10.1016/j.drugpo.2017.06.003 PMid:28688539 PMCid:PMC5722230

Pletcher MJ, Kertesz SG, Kohn MA, Gonzales R. Trends in opioid prescribing by race/ethnicity for patients seeking care in US emergency departments. JAMA. 2008; 299(1):70-8. https://doi.org/10.1001/jama.2007.64 PMid:18167408

Han B, Compton WM, Jones CM, Cai R. Nonmedical prescription opioid use and use disorders among adults aged 18 through 64 years in the United States, 2003-2013. JAMA. 2015; 314(14):1468-78. https://doi.org/10.1001/jama.2015.11859 PMid:26461997

Altekruse SF, Cosgrove CM, Altekruse WC, Jenkins RA, Blanco C. Socioeconomic risk factors for fatal opioid overdoses in the United States: Findings from the Mortality Disparities in American Communities Study (MDAC). PloS one. 2020;15(1):e0227966. https://doi.org/10.1371/journal.pone.0227966 PMid:31951640 PMCid:PMC6968850

Klimas J, Gorfinkel L, Fairbairn N, et al. Strategies to identify patient risks of prescription opioid addiction when initiating opioids for pain: a systematic review. JAMA Network Open. 2019; 2(5):e193365. https://doi.org/10.1001/jamanetworkopen.2019.3365 PMid:31050783 PMCid:PMC6503484

Turk DC, Swanson KS, Gatchel RJ. Predicting opioid misuse by chronic pain patients: a systematic review and literature synthesis. The Clinical Journal of Pain. 2008; 24(6):497-508. https://doi.org/10.1097/AJP.0b013e31816b1070 PMid:18574359

Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, Pickering RP, Kaplan K. Prevalence and co-occurrence of substance use disorders and independentmood and anxiety disorders: Results from the national epidemiologic survey on alcohol and relatedconditions. Archives of General Psychiatry. 2004; 61(8):807-16. https://doi.org/10.1001/archpsyc.61.8.807 PMid:15289279

Centers for Disease Control and Prevention. Opioid prescribing; Where you live matters. 2017. Accessed February 28 2024. https://www.cdc.gov/vitalsigns/pdf/2017-07-vitalsigns.pdf

Centers for Disease Control and Prevention. United States dispensing rate maps. 2023. Accessed February 28 2024. https://www.cdc.gov/drugoverdose/rxrate-maps/index.html

Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain-United States, 2016. JAMA. 2016;315(15):1624-1645. https://doi.org/10.1001/jama.2016.1464 PMid:26977696 PMCid:PMC6390846

Bach P, Hartung D. Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders. Addiction Science & Clinical Practice. 2019;14(1):30. https://doi.org/10.1186/s13722-019-0158-0 PMid:31474225 PMCid:PMC6717996

Hartung DM, Johnston KA, Hallvik S, et al. Prescription opioid dispensing patterns prior to heroin overdose in a state Medicaid program: a case-control study. Journal of General Internal Medicine. 2020; 35:3188-96. https://doi.org/10.1007/s11606-020-06192-4 PMid:32935311 PMCid:PMC7661590

Compton WM, Jones CM, Stein JB, Wargo EM. Promising roles for pharmacists in addressing the US opioid crisis. Research in Social and Administrative Pharmacy. 2019; 15(8):910-6. https://doi.org/10.1016/j.sapharm.2017.12.009 PMid:29325708 PMCid:PMC7373345

Iwuchukwu OF, Kim D. Prevention better than cure: expanding on pharmacists' role in prescription opioid overdose and addiction management. American Journal of Pharmacotherapy and Pharmaceutical Sciences. 2023; 2. https://doi.org/10.25259/AJPPS_2023_022

Hartung DM, Hall J, Haverly SN, et al. Pharmacists' role in opioid safety: a focus group investigation. Pain Medicine. 2018; 19(9):1799-806. https://doi.org/10.1093/pm/pnx139 PMid:29016883 PMCid:PMC6659018

So R, Al Hamarneh Y, Barnes M, et al. The status of naloxone in community pharmacies across Canada. Canadian Pharmacists Journal/Revue des Pharmaciens du Canada. 2020; 153(6):352-6. https://doi.org/10.1177/1715163520958435 PMid:33282025 PMCid:PMC7689620

Babor TF, McRee BG, Kassebaum PA, Grimaldi PL, Ahmed K, Bray J. Screening, Brief Intervention, and Referral to Treatment (SBIRT): toward a public health approach to the management of substance abuse. Alcohol/Drug Screening and Brief Intervention. 2023; 4:7-30. https://doi.org/10.1300/J465v28n03_03 PMid:18077300

Cochran G, Field C, Lawson K, Erickson C. Pharmacists' knowledge, attitudes and beliefs regarding screening and brief intervention for prescription opioid abuse: a survey of Utah and Texas pharmacists. Journal of Pharmaceutical Health Services Research. 2013; 4(2):71-9. https://doi.org/10.1111/jphs.12013 36. Cochran G, Rubinstein J, Bacci JL, Ylioja T, Tarter R. Screening community pharmacy patients for risk of prescription opioid misuse. Journal of Addiction Medicine. 2015; 9(5):411. https://doi.org/10.1097/ADM.0000000000000148 PMid:26291546 PMCid:PMC4725054

D'Onofrio G, Chawarski MC, O'Connor PG, et al. Emergency department-initiated buprenorphine for opioid dependence with continuation in primary care: outcomes during and after intervention. Journal of General Internal Medicine. 2017; 32:660-6. https://doi.org/10.1007/s11606-017-3993-2 PMid:28194688 PMCid:PMC5442013

Hargraves D, White C, Frederick R, et al. Implementing SBIRT (Screening, Brief Intervention and Referral to Treatment) in primary care: lessons learned from a multi-practice evaluation portfolio. Public Health Reviews. 2017; 38(1):1-1. https://doi.org/10.1186/s40985-017-0077-0 PMid:29450101 PMCid:PMC5809898

Gondora N, Sanyal C, Carter C, et al. The role of pharmacists in opioid stewardship: Protocol. Research in Social and Administrative Pharmacy. 2021;17(5):993-6. https://doi.org/10.1016/j.sapharm.2020.06.027 PMid:33773640

Bratberg JP, Smothers ZP, Collins K, Erstad B, Ruiz Veve J, Muzyk AJ. Pharmacists and the opioid crisis: A narrative review of pharmacists' practice roles. Journal of the American College of Clinical Pharmacy. 2020; 3(2):478-84. https://doi.org/10.1002/jac5.1171

Akers JL, Hansen RN, Oftebro RD. Implementing take-home naloxone in an urban community pharmacy. Journal of the American Pharmacists Association. 2017; 57(2): S161-7. https://doi.org/10.1016/j.japh.2017.01.006 PMid:28202384

Duvivier H, Gustafson S, Greutman M, et al. Indian Health Service pharmacists engaged in opioid safety initiatives and expanding access to naloxone. Journal of the American Pharmacists Association. 2017; 57(2): S135-40. https://doi.org/10.1016/j.japh.2017.01.005 PMid:28292501

Chaudhary S, Compton P. Use of risk mitigation practices by family nurse practitioners prescribing opioids for the management of chronic nonmalignant pain. Substance Abuse. 2017; 38(1):95-104. https://doi.org/10.1080/08897077.2016.1265038 PMid:27897471

Volkow ND, Jones EB, Einstein EB, Wargo EM. Prevention and treatment of opioid misuse and addiction: a review. JAMA Psychiatry. 2019; 76(2):208-16. https://doi.org/10.1001/jamapsychiatry.2018.3126 PMid:30516809

Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harvard review of psychiatry. 2015 Mar 1;23(2):63-75. https://doi.org/10.1097/HRP.0000000000000075 PMid:25747920

Viswanathan M, Kahwati LC, Golin CE, et al. Medication therapy management interventions in outpatient settings: a systematic review and meta-analysis. JAMA Internal Medicine. 2015;175(1):76-87. https://doi.org/10.1001/jamainternmed.2014.5841 PMid:25401788

Cobaugh DJ, Gainor C, Gaston CL, et al. The opioid abuse and misuse epidemic: implications for pharmacists in hospitals and health systems. American Journal of Health-System Pharmacy. 2014; 71(18):1539-54. https://doi.org/10.2146/ajhp140157 PMid:25174015

Cochran G, Gordon AJ, Field C et al. Developing a framework of care for opioid medication misuse in community pharmacy. Res Social Adm Pharm. 2016; 12:293-301. https://doi.org/10.1016/j.sapharm.2015.05.001 PMid:26048710 PMCid:PMC4726478

Tewell R, Edgerton L, Kyle E. Establishment of a pharmacist-led service for patients at high risk for opioid overdose. Am J Health-Syst Pharm. 2018; 75:376-83. https://doi.org/10.2146/ajhp170294 PMid:29523534

Thakur T, Frey M, Chewning B. Pharmacist services in the opioid crisis: current practices and scope in the United States. Pharmacy. 2019; 7(2):60. https://doi.org/10.3390/pharmacy7020060 PMid:31200469 PMCid:PMC6632048